Damen JA, Pajouheshnia R, Heus P, Moons KGM, Reitsma JB, Scholten RJPM, Hooft L, Debray TPA. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 2019 Jun 13;17(1):109. doi: 10.1186/s12916-019-1340-7
Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, Altman DG, Moons KGM, Hooft L. Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement. BMC Med. 2018 Jul 19;16(1):120. doi: 10.1186/s12916-018-1099-2
Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos-Meade J, Brown JMY, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep;70(17):1518-27.
Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high risk patients. Am J Health Syst Pharm. 2009 Oct;66(19):1711-7. doi: 10.2146/ajhp080325.
Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009 Mar 1;66(5):469-80.
Heyes A. Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy. Semin Oncol. 2004 Jun 1;31(Suppl. 9):16-22.